2017-12-22 21:27:19 UTC

2018 AGA Postgraduate Course Online Sessions


Online Sessions from the 2018 AGA Postgraduate Course: From Abstract to Reality keep you up to date in a rapidly changing field. Content will include the assessment of current approaches to treating several disease states including hot topics, disorders of the gut and upper GI tract, functional GI disorders, liver and pancreatic biliary disease, inflammatory bowel diseases (IBD) and hepatitis. A variety of AGA resources will be incorporated into this year’s course to help you distill guidelines, clinical research articles and emerging technology into everyday practice.

Product Features

  • Complete audio track of the general session lectures and select breakout sessions along with all slides. 
  • Associated quizzes can be completed to earn AMA PRA Category 1 Credits™ and Maintenance of Certification (MOC) points.
  • Internet connection needed to watch sessions on-demand.

Pre-Order Now and Save

You save more by pre-ordering the 2018 resources before the live course takes place in June 2018. Pre-ordering is only available in conjunction with AGA Postgraduate Course or DDW® 2018 registration. You can also view a full list of resources. Online sessions will be available to watch starting in fall 2018.

AGA Member: $95
Nonmember: $110

Register and pre-order now

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other health care professionals who treat GI disorders.

More on CME Credit

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

Final days to save on AGA Postgraduate Course

April 10, 2018

Early bird deadline is April 18 – last chance to save $75.

The Development and Approval of Inflectra, a Biosimilar to Remicade: Case Presentation

April 3, 2018

In this on-demand webinar, Sue Lim, MD of the FDA provides a general review of the requirements for a biosimilar 351(k) application and discusses the approval process for Inflectra.